- AU$33.90m
- -AU$33.93m
- AU$14.60m
Brief: Immutep Posts FY Loss Attributable A$61.4 Million
Brief: Immutep Gets FDA Nod to Advance Eftilagimod Alfa in Head & Neck Cancer (CPS <1)
Brief: Immutep’S Efti With Radiotherapy & KEYTRUDA® Meets Primary Endpoint In Phase 2 For Soft Tissue Sarcoma
Brief: Immutep Completes Patient Enrolment For INSIGHT-003
Brief: Immutep Announces Initial Safety Data From First-In-Human Phase I Trial Evaluating IMP761
Australia's Immutep rises on 3-week high after initiation of phase-3 trial
Brief: Positive Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting
Brief: Immutep Announces First-In-Human Phase I Study Of IMP761 Progresses To Dose Escalation Portion Of Trial
Brief: IMMUTEP Ltd Got EUR 2.2 Million Research And Development Tax Incentive Payment In Cash From French Government
Brief: Immutep Posts FY Loss Attributable A$42.7 Mln
Brief: Immutep Announces First Participant Dosed In Phase I Study Of Imp761
Brief: Immutep Announces Successful Meeting With FDA On TACTI-004 Phase III Trial Design
Brief: Immutep Announces Positive Feedback Received From US FDA
Brief: Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody
Australia's Immutep rises on positive results from cancer trial
Brief: Immutep Reports Positive Results In First Line Head And Neck Squamous Cell Carcinoma Patients With Negative Pd-L1 Expression
Brief: Immutep Signs Exclusive License Agreement With Cardiff University For Next Generation Anti-Lag-3 Molecules For Cancer
Australia's Immutep falls on discounted placement
Brief: Immutep Enters Clinical Trial Collaboration And Supply Agreement With Merck & Co